The U.S. intravenous immunoglobulin (IVIG) market was valued at USD 5.74 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030. Rising demand for immunoglobulin replacement therapy, particularly for primary immunodeficiency diseases (PIDD), and the introduction of new products are supporting market growth. Expanded treatment options,...